СНИЖЕНИЕ СИСТОЛИЧЕСКОГО АРТЕРИАЛЬНОГО ДАВЛЕНИЯ: ВСЕ ЛИ ПРЕПАРАТЫ ОДИНАКОВЫ?
https://doi.org/10.20996/1819-6446-2005-1-2-54-60
Аннотация
В статье приводятся данные крупных проспективных исследований, свидетельствующие о более значимой роли повышения систолического АД в прогнозе артериальной гипертонии. Делается вывод о том, что диуретики на сегодняшний день являются наиболее перспективными препаратами для снижения систолического АД. Среди диуретиков индапамид SR (Арифон ретард) выделяется своей эффективностью и безопасностью.
Об авторе
С. В. Недогода
Волгоградский государственный медицинский университет
Россия
Кафедра терапии и семейной медицины ФУВ
Россия
Кафедра терапии и семейной медицины ФУВ
Список литературы
1. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001; 103(9):1245-9.
2. Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation. 1988;77(3):504-14.
3. Domanski M, Mitchell G, Pfeffer M, et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002;287(20):2677-83.
4. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J. 1999;138(3 Pt 2):211-9.
5. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13.
6. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-92.
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72.
8. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пере- смотр). Кардиоваск тер профилакт 2004; приложение: 1-20.
9. Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J Clin Hypertens (Greenwich). 2001;3(4): 211-6.
10. Kaplan NM. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther. 1996; 18(4):658-70.
11. Vetter W. Treatment of senile hypertension: the Fosinopril in Old Patients Study (FOPS). Am J Hypertens. 1997;10(10 Pt 2):255S-261S.
12. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288(12):1491-8.
13. Malacco E, Mancia G, Rappelli A, et al. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. 2003;12(3):160-7.
14. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.
15. Staessen JA, Fagard R, Thijs L, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-64.
16. Emeriau JP, Knauf H, Pujadas JO, A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens. 2001;19(2):343-50.
17. Leonetti G, Emeriau JP, Knauf H, et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin. 2005;21(1):37-46.
18. London G, Calvo C, Schmieder R. Antihypertensive efficacy of indapamide SR vs candesartan and amlodipine in hypertensive patients: the X-CELLENT main study. J Hypertens. 2004;22(suppl 2):S384.
19. London G, Calvo C, Schmieder R, Asmar R. Indapamide SR antihypertensive efficacy vs candesartan and amlodipine in isolated systolic hypertensive patients: the X-CELLENT ISH subset. J Hypertens. 2004;22(suppl 2):S113-S114.
20. London G, Calvo C, Schmieder R. Applanation tonometry: systolic blood pressure and pulse pressure (PP) under treatment with indapamide SR versus candesartan and amlodipine: the X-CELLENT tonometry study. J Hypertens. 2004;22(suppl 2):S275.
Рецензия
Для цитирования:
Недогода С.В. СНИЖЕНИЕ СИСТОЛИЧЕСКОГО АРТЕРИАЛЬНОГО ДАВЛЕНИЯ: ВСЕ ЛИ ПРЕПАРАТЫ ОДИНАКОВЫ? Рациональная Фармакотерапия в Кардиологии. 2005;1(2):54-60. https://doi.org/10.20996/1819-6446-2005-1-2-54-60
For citation:
Nedogoda S.V. SYSTOLIC BLOOD PRESSURE REDUCTION: DO ALL THE DRUGS HAVE THE SAME EFFICIENCY? Rational Pharmacotherapy in Cardiology. 2005;1(2):54-60. (In Russ.) https://doi.org/10.20996/1819-6446-2005-1-2-54-60
Просмотров:
22915
Послать статью по эл. почте 